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ABSTRACT 
 
IDENTIFYING CRITICAL GENES FOR CHOLESTEROL METABOLISM IN 
MACROPHAGES USING CRISPR-CAS9 WHOLE-GENOME SCREENS 
KEVIN WANNIARACHCHI 
2019 
 Macrophage foam cells contribute to atherosclerotic plaque formation, a 
pathology that underlies heart disease, peripheral arterial disease and stroke. Foam cells 
form when macrophages take up excessive amounts of low-density lipoprotein (LDL) 
leading to elevated cellular levels of neutral lipids, which are packaged into lipid droplet 
organelles. Despite the high public health priority motivating research of cardiovascular 
disease processes, current understanding of macrophage cholesterol metabolism 
including mechanisms of LDL uptake, cholesterol trafficking, lipid droplet biogenesis, 
lipid droplet degradation and cholesterol efflux is limited. Here, we implemented a 
CRISPR-Cas9 whole genome screening strategy to identify critical genes regulating 
macrophage cholesterol metabolism. Murine bone marrow derived macrophages 
(BMDM) were derived from transgenic mice expressing Cas9 protein and transduced 
with a pooled library of guide RNAs (sgRNA) that contained ~80,000 sgRNA targeting 
the majority of protein-coding genes in the mouse genome. BMDM were transduced with 
low viral multiplicity of infection to produce a single sgRNA insertion per cell. To 
identify gene disruptions conferring gain-of-function or loss-of-function effects on LDL 
uptake, cholesterol trafficking, or lipid droplet biogenesis, we exposed the mutant 
populations of BMDM to acetylated or oxidized LDL for 24 h, stained for cellular neutral 
lipid content using BODIPY 493/503 and sorted low- and high-fluorescence cells by flow 
 
   
 
 
 
vi 
cytometry. Similarly, to identify genes critical for lipid droplet degradation, cholesterol 
metabolism and cholesterol efflux, we exposed the BMDM to modified LDLs for 24 h 
followed by LDL removal and a 48-h chase. DNA from the sorted cells was deep 
sequenced to quantify sgRNA inserts. Bioinformatics and statistical analyses identified 
sgRNA inserts that were enriched in the low neutral lipid or high neutral lipid pools and 
generated ranked gene lists containing genes regulating cholesterol metabolism in 
macrophages. To validate the screen results, we made targeted gene disruptions in 
BMDM followed by staining and fluorescence microscopy of BODIPY and perilipin to 
verify the neutral lipid phenotype and evaluate lipid droplet morphology and cellular 
distribution. Of note, we highlight the identification of novel genes regulating neutral 
lipid levels in macrophages. Emc3 encodes an endoplasmic reticulum membrane 
complex protein, and when disrupted led to lower cellular neutral lipid content than 
wildtype cells. Whereas, Atg9a, an autophagy-related protein, when disrupted leads to 
higher neutral lipid due to inefficient neutral lipid clearance. In addition, gene set 
enrichment analysis (GSEA) analysis of screen results suggest that Golgi-conserved 
oligomeric complex and endoplasmic reticulum membrane complex proteins are critical 
for LDL processing. sgRNA for genes in these gene sets were enriched in the low 
fluorescence population in the 24-h oxidized or acetylated LDL conditions. Further, our 
screens identified many genes previously characterized in modified-LDL processing such 
as genes regulating receptor mediated clathrin-dependent endocytosis, Golgi-to-
endoplasmic reticulum trafficking, and autophagy-associated proteins as critical 
regulators for neutral lipids in BMDMs. Overall, these results provide new avenues for 
research to determine the mechanisms of cholesterol metabolisms in macrophages. 
 
   
 
 
 
1 
Chapter I 
 
 
Introduction and Critical Analysis:  
Mechanisms of LDL Uptake, Lipid Droplet Biogenesis, and Lipid Droplet 
Degradation 
 
 
Public health significance and overview of atherosclerosis pathophysiology 
 Atherosclerosis is the leading cause of death by cardiovascular disease in the 
United States and in western societies, and in the United States annually, approximately 
610,000 deaths are due to cardiovascular disease (Mozaffarian, Benjamin et al. 2015, 
Benjamin, Blaha et al. 2017, CDC 2019). Around 49% of Americans are subjected to at 
least one risk factor associated with cardiovascular disease such as high blood pressure, 
high-LDL cholesterol, and smoking (Mozaffarian, Benjamin et al. 2015, CDC 2019).  
However, statins (3-hydroxy-3-methylgluataryl coenzyme A (HMG-CoA) reductase 
inhibitors), which are widely prescribed to lower the risk of cardiovascular diseases, have 
low mortality prevention rates around 25% (Wilt, Bloomfield et al. 2004). This means 
that available treatments are ineffective for the majority of patients and highlight the need 
to find new therapeutic targets. 
Macrophages contribute to atherosclerotic pathogenesis and may be a target for 
new therapeutic strategies to treat cardiovascular diseases. In the onset of atherosclerosis, 
circulating monocytes are localized into artery walls and differentiate to phagocytic 
macrophages to clear modified lipoproteins, remove debris and dead cells resulting in the 
macrophage “foam cells” phenotype (Tabas 2002, Mestas and Ley 2008). Foam cell 
accumulation is associated with plaque formation, rupture and thrombosis, thus, 
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increasing the risk of cardiovascular diseases (Daugherty, Rateri et al. 2008, Neele, Van 
Den Bossche et al. 2015, Chistiakov, Melnichenko et al. 2017).   
 
Significance of this work  
 Cholesterol metabolism in macrophages is a function of low density lipoprotein 
(LDL) uptake, LDL degradation to derive free cholesterol, processing of free cholesterol 
by the endoplasmic reticulum to form lipid droplets, and degradation of lipid droplets for 
cellular needs and cholesterol efflux.  Modified LDLs binds to scavenger receptors and 
are trafficked by clathrin-mediated endocytosis (Chen, Wang et al. 2006, Infante, Wang 
et al. 2008, Zani, Stephen et al. 2015). The modified LDLs are degraded by endosomal 
maturation and lysosomal fusion where the activity of lysosomal lipases results in 
cholesterol that can be directed in vesicles to plasma membrane, trans Golgi apparatus, 
endoplasmic reticulum or be effluxed out of the cell (Tabas 2002). Excess cholesterol is 
esterified to form neutral lipids that are sequestered as lipid droplets in the endoplasmic 
reticulum as an energy storage mechanism as well as to prevent toxicity (Su, Dove De 
Fau - Major et al. 2005). Lipid droplets can be degraded via lipolysis or autophagy to 
derive cholesterol and free fatty acids by the action of cholesterol ester hydrolases 
(Ducharme and Bickel 2008, Nguyen and Olzmann 2017). However, current knowledge 
of critical regulators associated with the aforementioned processes are limited and as 
pointed out in Walther, Farese et al. there are many unaddressed questions including: 
how are lipid droplets formed in the endoplasmic reticulum, what regulates the process? 
How do lipases access lipid droplets during lipolysis? (Walther, Farese et al. 2012). 
 
   
 
 
 
3 
 Thus, there is a need for furthering the understanding of cellular processing of 
high levels of LDL-cholesterol and the consequent impacts on total cellular levels of 
neutral lipid and cholesterol metabolism. To contribute towards this, we implemented a 
series of CRISPR-Cas9 whole-genome screens to discover critical genes for neutral lipid 
metabolism in modified LDL exposed mouse bone marrow-derived primary macrophages 
(BMDM). Previous whole-genome screens to identify regulators of lipid droplet 
formation using RNA-interference (RNAi) in drosophila found ~1.5% of genes are 
associated with lipid droplet formation machinery and found a novel association of Arf-
COPI proteins involved in vesicular trafficking as an important determinant for lipid 
droplet morphology (Guo, Walther et al. 2008). However, a drawback of RNAi screens is 
that they have high off-target effects and low knockdown efficiency but CRISPR-Cas9 
screens allow for high on target and high gene disruption efficiency (Boettcher 2015).  
 CRISPR-Cas9 screens are a powerful technology to access the necessity of each 
gene towards these processes and simultaneously identify underlying biological pathways 
with higher efficiency compared to other existing whole-genome screening methods 
(Shalem, Sanjana et al. 2014, Chen, Sanjana et al. 2015). A comparison of CRISPR-Cas9 
screens versus RNA interference screens via shRNA for identifying essential genes in 
myelogenous leukemia cell line K562 revealed CRISPR-Cas9 screens identified 4,532 
essential genes compared to 3,130 from RNAi screens (Morgens, Deans et al. 2016).  
Therefore, we developed flow cytometry-based assays to identify changes in neutral lipid 
metabolism in BMDMs by scrutinizing the presence of neutral lipids using fluorescence 
staining. These assays were combined with CRISPR-Cas9 whole-genome screens and a 
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powerful bioinformatics pipeline to perform comparisons with high statistical power and 
identify critical genes associated with these processes. 
   
Macrophage exposure to LDL leads to elevated cholesterol trafficking, lipid droplet 
formation and elevated neutral lipid metabolism. 
 Scavenger receptors, mainly class A scavenger receptors such as macrophage 
scavenger receptor 1 (Msr1) and CD36, are expressed on the surface of macrophages 
where they bind modified LDLs and are subsequently endocytosed in clathrin-coated 
vesicles (Chen, Wang et al. 2006, Infante, Wang et al. 2008, Zani, Stephen et al. 2015). 
LDL is degraded in lysosomes to derive cholesterol, and Niemann Pick Type C (NPC) 
lysosomal surface proteins are important regulators of this process (Cruz, Sugii et al. 
2000, Frolov, Zielinski et al. 2003). Cholesterol binds to the N-terminal domain of NPC1 
inserting it to the lysosomal membrane, and there is a bidirectional transfer between 
NPC1 and its counterpart NPC2 facilitating cholesterol shuttling to the endoplasmic 
reticulum (Infante, Wang et al. 2008). Non-functional NPC1 in human fibroblasts and 
hamster ovary cells leads to the accumulation of cholesterol in late endocytic-lysosomal 
compartments and could potentially play a similar role in BMDMs. (Liscum 1989) (Cruz, 
Sugii et al. 2000). Proteins responsible for regulating the trafficking of cholesterol from 
lysosomes to the cytoplasm or other organelles are yet to be elucidated (Du and Yang 
2013).  
 Cholesterol is shuttled to the endoplasmic reticulum to be esterified and to prevent 
cholesterol toxicity (Tabas 2002). Cholesterol-esterification in the endoplasmic reticulum 
is regulated by the enzyme acyl-CoA acyltransferase (ACAT1, gene ID: Soat1)  (Su, 
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Dove De Fau - Major et al.). Pharmacological inhibitors of ACAT1 in mice and rabbit 
models lead to an increase in foam cell formation and atherosclerotic plaque (Perrey, 
Legendre et al. 2001, Lu, Yuan et al. 2011). The synthesized cholesteryl esters are stored 
within the endoplasmic reticulum phospholipid bilayers and upon reaching a certain 
threshold they are packaged and released to the cytosol as lipid droplets (Ohsaki, Suzuki 
et al. 2014). The mechanisms and regulators underlying the processes of lipid droplet 
biogenesis, including interactions of lipid droplets with other organelles is yet to be 
understood (Herker and Ott 2012, Walther, Farese et al. 2012) 
 Several models for the biogenesis of lipid droplets on the endoplasmic reticulum 
have been suggested (Thiam, Farese et al. 2014). One such model posits that lipid droplet 
emergence from the ER is a spontaneous physical process resulting from cholesteryl ester 
accumulation within the bilayers of the endoplasmic reticulum, which may lower the 
surface tension to a point where lipid droplets form and are released from the bilayers. 
(Thiam, Farese et al. (2013). Experiments supporting the ER cup model used freeze-
fracture immunocytochemistry in lipid-laden macrophages to show that emerging lipid 
droplets remain embedded in the endoplasmic reticulum bilayer until a critical mass is 
reached causing the budding off to the cytosol (Robenek, Hofnagel et al. 2006).  
 Lipolysis and autophagy mediate the process of lipid droplet degradation to derive 
cholesterol and fatty acids (Ducharme and Bickel 2008, Nguyen and Olzmann 2017). 
Lipid droplet autophagy is activated by adipose triglyceride lipase (ATGL) in 
hepatocytes (Sathyanarayan, Mashek et al. 2017). Similarly, LC3 (an autophagosome 
marker) has been observed to co-localize with lipid droplets and inhibition of autophagy 
decreases lipid droplet delivery to lysosomes (Ouimet, Franklin et al. 2011). Degraded 
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LDL-C can be used for cellular energy needs or be effluxed via ABCA1 (Su, Dove De 
Fau - Major et al. , Oram 2003). 
 
 
 
Figure 1. Cholesterol trafficking and metabolism following exposure of macrophages to modified 
LDLs. Scavenger receptors mediate clathrin-dependent endocytosis of modified LDL followed by 
endocytic trafficking and fusion of LDL carrying vesicles with lysosomes. Within the lysosomes, LDL 
particles are degraded to derive free cholesterol which is then directed either to the plasma membrane 
and effluxed, or to the endoplasmic reticulum to be esterified and sequestered in lipid droplet organelles. 
Lipid droplets can be degraded by autophagy and/or lipolysis to derive cholesterol and free fatty acids 
that can be used for cellular needs or be effluxed from the cell and transported via HDL to the liver for 
biliary excretion. 
 
 
CRISPR-Cas9 technology allows for efficient gene disruptions and whole genome 
screens 
 Clustered regularly interspaced short palindromic repeat (CRISPR) along with the 
endonuclease, Cas9, are part of bacterial immune system that has been successfully 
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adopted by scientists to achieve highly efficient gene disruption at targeted DNA loci 
(Fonfara, Le Rhun et al. 2014). Here, a sequence of  RNA (sgRNA) is targeted to a 
complementary gene of interest where a double stranded break in the DNA is created by 
the Cas9 endonuclease, leading to activation of DNA repair pathways such as non-
homologus end-joining which is error-prone and causes insertions and deletions at a high 
frequency.  If made in an early exon, frame shift mutations will result, disrupting the 
gene.  (Ran, Hsu et al. 2013) 
  We utilized a lentiviral CRISPR-Cas9 transduction strategy to achieve efficient 
and high gene disruption rate in Cas9-expressing BMDMs (Shalem, Sanjana et al. 2014). 
Here the use of transgenic Cas9-expressing mice to derive BMDMs that minimizes the 
payload in the viral particles to sgRNA and tracRNA allowing for high gene disruption 
efficiency. Viral particles containing sgRNA packaged in the 293T packaging cells with a 
high titer of viral particles were harvested as described in methods. Using this strategy we 
used the Brie library (Addgene) to conduct a series of CRISPR-Cas9 whole genome 
screens. Brie library of sgRNAs composed of ~80,000 sgRNA targeting ~20,000 protein-
encoding mice genes (4 sgRNA targeting each gene) and ~1000 control sgRNAs to 
transduce ~100 million Cas9 expressing BMDMs per screen (Doench, Fusi et al. 2016). 
Cas9 expressing BMDMs were transduced with the Brie library at a low multiplicity of 
infection to derive mutant populations of BMDMs. These mutant populations were 
exposed to modified low-density lipoproteins to increase neutral lipid metabolism and 
elevate lipid droplet formation for 24 h. For neutral lipid metabolism and cholesterol 
efflux screens post LDL exposure cells were chased for 36-48 h in LDL-free media. The 
lipophilic neutral lipid dye BODIPY 493/503 was used to stain neutral lipids in the 
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mutants followed by flow cytometry aided cell sorting into groups based on neutral lipid 
content. We used next generation sequencing to sequence the sgRNA inserts from sorted 
groups and using a powerful bioinformatics pipeline we identified critical genes 
associated with neutral lipid metabolism. We used CRISPR-Cas9 transduction technique 
to carry out single gene disruptions of identified hits from CRISPR-Cas9 whole genome 
screens.  
 In conclusion, given the public health significance and the dearth of mechanistic 
understandings in macrophage biology it is vital to design and implement experiments 
powerful to encompass all vital aspects in macrophage cholesterol metabolism. Here, we 
implemented highly efficient CRISPR-Cas9 whole-genome screens to identify critical 
genes for cholesterol metabolism and we provide ranked lists of critical genes leading 
high or low neutral lipids in BMDMs as well as provide evidence for their phenotypes 
from targeted sgRNA disruption. 
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Chapter II 
 
Identifying Critical Genes for Cholesterol Metabolism in Macrophages Using 
CRISPR-Cas9 Whole-Genome Screens  
 
Introduction 
 Cardiovascular diseases, particularly atherosclerosis, are a leading cause of death 
in the United States and globally (Benjamin, Blaha et al. 2017). Currently, statins, a class 
of 3-hydroxy-3-methylgluataryl coenzyme A (HMG-CoA) reductase inhibitors, are 
widely prescribed to treat cardiovascular diseases (Baigent, Keech et al. 2005). However, 
statins have low mortality prevention rates (~25%) (Wilt, Bloomfield et al. 2004, 
Baigent, Keech et al. 2005) thus highlighting the need for better drug targets to treat 
atherosclerosis. During early atherosclerosis progression, high circulating low-density 
lipoprotein (LDL)-cholesterol results in the accumulation of  lipid-laden macrophages in 
the vascular intima and development of fatty streaks in artery walls (Moore and Tabas 
2011). Lipid-laden macrophages are caused by high accumulations of LDL-derived 
cholesterol, debris and dead cells within the vascular intima (Webb and Moore 2007). 
Given the key role of macrophages in mediating the progression of atherosclerosis, these 
cells are potential therapeutic targets for treating this disease. 
 In macrophages, cellular levels of free cholesterol and esterified cholesterol are a 
function of the rates of LDL uptake, cholesterol trafficking, lipid droplet formation, 
degradation, and cholesterol efflux. Macrophages endocytose native LDL via LDL 
receptors and endocytose modified LDL species, such as oxidized and acetylated LDL, 
via a number of plasma membrane receptors including scavenger receptors. LDL-
receptor (LDL-R) recognizes and binds to apoprotein B100 in native LDL, while 
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scavenger receptors such as CD36 (scavenger receptor class-B member 3) and SR-A 
(class-A scavenger receptor class-A member 1) mediate uptake of modified LDLs such as 
oxidized LDL (OxLDL) or acetylated LDL (AcLDL) (Chen, Wang et al. 2006, Infante, 
Wang et al. 2008, Zani, Stephen et al. 2015). After endocytic trafficking to the lysosome, 
free cholesterol is derived from the LDL, and excess cholesterol, which is slightly polar, 
is esterified, thus, rendering its charge neutral. These neutral cholesterol esters are 
sequestered in lipid droplet organelles (Maxfield and Tabas 2005). In reverse cholesterol 
transport, lipid droplets are degraded by autophagy and/or lipolysis to derive free 
cholesterol that can be effluxed out of the cells to acceptors such as high-density 
lipoproteins (HDL) and subsequently delivered to the liver for biliary excretion 
(Kwiterovich 2000, Su, Dove et al. 2005, Dong and Czaja 2011).The role of autophagy in 
the degradation of lipid droplets has been shown through association of the 
autophagosome marker microtubule-associated protein 1A/1B-light chain 3 (LC3) with 
lipid droplets, and by the demonstration that inhibition of autophagy decreases lipid 
droplet delivery to lysosomes (Ouimet, Franklin et al. 2011). 
Early observations that high circulating HDL levels correlated with lower 
cardiovascular disease highlight the importance of efficient reverse cholesterol transport 
(Rohatgi, Khera et al. 2014) and led to the development of drugs such as niacin, fibrates, 
and inhibitors of cholesterol ester transfer protein (CETP) to increase HDL (Keene, Price 
et al. 2014). Neutral lipid clearance by cholesteryl ester hydrolysis is the rate-limiting 
step in reverse cholesterol transport in lipid droplet laden-macrophages (Hutchins and 
Heinecke 2015). Cholesterol ester hydrolases such as hormone-sensitive lipase (Lipe), 
carboxylesterase 3 (Ces3), and neutral cholesterol-ester hydrolase 1 (Nceh1) mediate the 
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hydrolysis of cholesterol esters (Hutchins and Heinecke 2015). Furthermore, previous 
work has shown that the inhibition of Nceh1 in lipid-laden macrophages leads to 
increased lipid droplet accumulation (Sakai, Igarashi et al. 2014). However, current 
understanding is limited regarding other cellular events and mechanisms critical for these 
processes in macrophages. 
 Given the public health importance of preventing atherosclerotic disease 
progression, and the dearth of molecular mechanistic understanding of these processes in 
cells of all types, but especially macrophages, we implemented a series of CRISPR-Cas9 
whole genome screens to discover critical mediators of cholesterol metabolism in bone 
marrow-derived macrophages. CRISPR-Cas9 whole-genome screens are more powerful 
in identifying critical genes compared to other genome screening techniques because of 
its high on-target rates and high levels of complete gene disruption (Shalem, Sanjana et 
al. 2014, Boettcher 2015, Morgens, Deans et al. 2016). In this technology, guide RNA 
(sgRNA), which are complementary to target genes, direct the Cas9 endonuclease 
enzyme to make double-stranded breaks in DNA leading to insertions or deletions during 
DNA repair and subsequently disrupting expression of the protein (Sanjana, Shalem et al. 
2014).  
 Here, we have identified critical genes and cellular pathways that cause defects in 
macrophage cholesterol metabolism by scrutinizing neutral lipid content in BMDM via a 
series of whole-genome CRISPR-Cas9 screens. To this end, we used a two-pronged 
approach whereby we identified loss-of-function or gain-of-function phenotypes in 
BMDM transduced with the Brie sgRNA library under the following conditions:  
1) following a 24-h AcLDL or OxLDL exposure, or  
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2) following 24-h AcLDL or OxLDL and a 36-48 h chase following removal of 
LDL.  
Specifically, in order to identify critical genes for LDL uptake, cholesterol 
trafficking, and lipid droplet formation, we transduced a population of BMDMs with the 
Brie sgRNA library, exposed them to AcLDL or OxLDL for 24 h and stained them with 
the neutral lipid marker BODIPY 493/503. Using flow cytometry, we identified sgRNA 
enriched in low- and high-fluorescence populations corresponding to high- or low-neutral 
content. To identify critical genes for lipid droplet degradation and cholesterol efflux, we 
identified sgRNA enriched in BMDM with low or high neutral lipid following the LDL 
removal and the post-LDL chase. Our screens identified novel Emc3, Atg9a and organelle 
complexes such as the endoplasmic reticulum associated endoplasmic reticulum 
membrane complex and Golgi-apparatus conserved oligomeric complex, as well as 
known genes associated with cholesterol metabolism such as Msr1, Soat1, and, Abca1.  
 
Methods 
Reagents 
BMDM were cultured in bone-marrow medium (BMM) containing Dulbecco’s Modified 
Eagle Medium (ATCC 30-2002, American Type Culture Collection, Manssas, VA), 20% 
heat-inactivated fetal bovine serum (Atlanta Biologicals) and 30% L-cell supernatant 
(Stanley and Heard 1977) a source of colony-stimulating factor-1, 10,000 IU penicillin 
and 10 mg/mL streptomycin (Corning, Manassas, VA), and 5.7 mM 2-mercaptoethanol. 
DPBS without calcium or magnesium was purchased from GE Healthcare Life Sciences, 
Pittsburgh, PA. AcLDL (Alfa Aesar, Haverhill, MA) and OxLDL were from (Alfa Aesar, 
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Haverhill, MA). Lipid droplets were stained with BODIPY 493/503 (4,4-Difluoro-
1,3,5,7,8-Pentamethyl-4-Bora-3a,4a-Diaza-s-Indacene) (Invitrogen). Perilipin antibody 
(ab108323), was from Abcam. Cyclosporin A (30024, Sigma). Mouse Brie CRISPR 
knockout pooled library developed by David Root and John Doench was obtained from 
Addgene (Addgene #73633) (Doench, Fusi et al. 2016). The blocking/permeabilization 
buffer for immunofluorescence was prepared with 1% BSA (BP1600-100, Fisher 
BioReagents), 0.1% saponin (558255-100GM, EMD Millipore), 0.02%  sodium azide 
(J21610-22, Thermo Scientific) in DPBS 
 
Bone marrow-derived macrophage isolation and culture 
Transgenic mice with a Rosa26-Cas9 knock-in on a C57BL/6J background were received 
from Jackson Laboratories (Stock No. 026179, Bar Harbor, ME). Mice were euthanized 
using CO2, femurs were dissected from the mice and bone marrow was harvested 
(Swanson 1989) by flushing Dulbecco’s phosphate buffer saline (DPBS) without calcium 
or magnesium (GE Healthcare Life Sciences, Pittsburgh, PA) through the bone using a 
needle and syringe. Cells were plated in non-tissue culture treated, sterile dishes and 
incubated at 37°C with 5% CO2. Additional BMM was added to the cells on day 2 post-
isolation. Following cell adherence to the dish, on day 4, the medium was completely 
removed and fresh BMM added to the culture. For cells undergoing lentiviral 
transductions, viral supernatants were added to the cells on day 4-6 of culture. 
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CRISPR-Cas9 whole-genome screen workflow  
 
 
Figure 1. Workflow of CRISPR-Cas9 whole-genome screens leading to identification of critical 
genes for cholesterol metabolism in bone marrow-derived macrophages. Cas9-expressing murine 
BMDMs were transduced with the Brie sgRNA library targeting ~20,000 protein coding genes with 4 
sgRNA per gene in the mouse genome. Following puromycin selection, BMDMs were cultured for 8-10 
days to deplete mRNA and proteins in gene-disrupted cells. To identify genes regulating cholesterol 
uptake and lipid droplet biogenesis, BMDMs were exposed to AcLDL or OxLDL for 24 h, stained with 
BODIPY 493/503 and high- and low-fluorescence cells were sorted. To identify genes critical for neutral 
lipid flux as cholesterol via  lipid droplet degradation, cells were chased in culture medium for 36-48 h  
post LDL removal and high- and low- fluorescence cells were sorted. sgRNA inserts from the high- and 
low-fluorescence groups from the 24-h LDL exposure and the post-LDL48-h chase, along with sgRNA 
library plasmid DNA (input), BMDMs prior to LDL exposure (pre-LDL) and prior to sorting (pre-sort) 
samples were all sequenced by next generation sequencing. sgRNA inserts were mapped to the sgRNA 
library and mouse genome. Following statistical analyses, genes were ranked based on enrichment in the 
low- or high-fluorescence pools corresponding to high or low neutral lipid content. Low fluorescence = 
low neutral lipid in cells following gene disruption. High fluorescence = high neutral lipid in cells 
following gene-disruption. 
 
 
Lentiviral transduction of Brie pooled sgRNA library 
Brie library amplification, lentiviral production, and functional titer determination were 
performed as previously described (Joung, Konermann et al. 2017) with minor 
modifications. Briefly, the Brie library was amplified in Stable 3 competent E. coli 
(Thermofisher) and subjected to next-generation-sequencing (NGS) to determine the 
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distribution of sgRNAs in the library. To produce Lentivirus, 1.8 x 106 NIH 293T cells 
were seeded in six 10-cm plates and transfected the following day with 6 µg sgRNA 
pooled library in lentiGuide-Puro (Addgene# 73633), 6 µg psPAX2 plasmid, 1 µg 
pVSVG plasmid, and 0.024 mg polyethyleneimine (PEI). After 48 h, the lentivirus was 
harvested, centrifuged, and aliquoted into multiple 15 mL tubes and stored at -80o C or -
150o C. The functional titer of the lentivirus was determined by live-cell counting after 
puromycin selection. For lentivirus infection, BMDM expressing Cas9-GFP were 
transduced with the Brie library at a multiplicity of infection (MOI) = 0.3. Approximately 
2.5 x107  to 5 x107  cells were transduced with 8 x 106  or 16 x 106  transduction units 
(TUs) to achieve 100-200-fold representation of each sgRNA. After 48 h, cells were 
selected with puromycin (5 µg/mL) for two days and were cultured for at least seven 
more days before the neutral lipid assay and cell sorting. 
  
Neutral lipid assay and cell sorting 
Following lentiviral transduction, sgRNA inserted cells were exposed to AcLDL (50 
µg/ml) or OxLDL (100 µg/ml) for 24 h. We scrutinized neutral lipid content in two 
conditions: 1) 24-h LDL exposure and 2) 36-48-h chase following LDL removal. For 
each condition we treated cells with AcLDL for two replicate populations and treated 
cells with OxLDL for one replicate for each condition. Before group isolation by 
fluorescence activated cell sorting BMDMs were stained with 5 µM BODIPY (493/503), 
a neutral lipid dye staining LDs, diluted in DMEM for 5 mins, washed once with cold 
DPBS (-Ca/-Mg) and detached with DPBS (-Ca/-Mg). Next, sorting was done by BD 
FACs JAZZ cell sorter based on low or high BODIPY fluorescence (~5 x 106 
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cells/group) in each screen. The lower 25% of cells with low fluorescence and higher 
25% of cells with high fluorescence were sorted in each group described below. 
In each population the isolated groups of cells were as follows, 
(1) High BODIPY fluorescence (High neutral lipids) 
(2) Low BODIPY fluorescence (Low neutral lipids) 
(3) Prior to sorting (~10%)  (pre-sort) 
(4) Plasmid DNA of the input brie library (input) 
 
PCR and next-generation sequencing of gRNA inserts 
Genomic DNA was extracted from unsorted and sorted cells using the GeneJET genomic 
DNA extraction kit (#K0721 Thermofisher) and the sgRNA library was amplified by a 
single-step PCR protocol (Broad Institute) for NGS using barcoded primers with 
staggered sequences. PCR product from multiple PCR reactions was pooled and gel 
purified and quantified by Qubit Fluorometer and subjected to sequencing on Illumina 
Nextseq 500 with 75 reads. Sequencing quality control from FASTQC (Andrews 2010), 
read count summaries and mapping data from MAGeCK-VISPR can be found in the 
(Supplemental Figure 2-3). Cut adapt, version 2.3 (Martin 2011) was used to remove 
sequencer adapter regions to produce files which contained 20 basepair read segment of 
gRNA inserts with no mismatch tolerated.  
Statistical analysis of sequencing data and gene ranking 
Model-based Analysis of Genome-wide CRISPR-Cas9 Knockouts (MAGeCK), version 
0.5.9 (Li, Xu et al. 2014), was used to map gRNA insert reads to their corresponding 
sgRNA inserts to the Brie library and corresponding gene names with no mismatches 
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tolerated. MAGeCK-RRA analysis produced a ranked list of genes by comparison of read 
enrichment (Li, Xu et al. 2014). Using the -count function in MAGeCK, the gene counts 
were tallied to produce read count tables for each group. The -test command was used to 
rank gRNA enriched by comparison of read counts between each group. To compare 
replicate screens, paired function was used (-test -paired commands). ~1000 control non-
coding sgRNA inserts were specified for normalization and generating null distribution 
of RRA were specified by -control function. Results from MAGeCK-RRA test can be 
found in the Supplementary table-1. MAGeCK-VISPR (Li, Koster et al. 2015), a 
MAGeCK tool that allows visualization of quality control and screen design of CRISPR-
Cas9 whole-genome screens, was used to visualize the read counts mapped to the Brie 
library, visualize read counts for each gRNA insert, and, generate correlation assessment 
of reads in each group (Supplement Figure 2F-3F). 
 
Pathway enrichment analysis and differential gene expression analysis  
Ranked lists of genes for each screen were used to identify biologically enriched 
pathways using gene set enrichment analysis (GSEA) available on the web-based 
Integrated Differential Expression and Pathway Analysis (iDEP.9) website (Mootha, 
Lindgren et al. 2003, Subramanian, Tamayo et al. 2005, Ge 2017). Briefly, GSEA  
groups gene sets by common biological function and compares if gene sets occur towards 
the top or bottom of the ranked list and assign enrichment scores. The normalized 
enrichment score (NES), based on gene set enrichment scores for gene set permutations, 
was used to compare analysis results where a positive score reflects gene sets represented 
 
   
 
 
 
25 
at the top of the ranked list and a negative score reflects gene sets represented towards the 
bottom of the list.  
 
Lentiviral mediated CRISPR-Cas9 gene disruptions 
To make targeted CRISPR-Cas9 gene disruptions for screen validation, sgRNAs from the 
Brie library were selected based on previously tabulated sgRNA counts and on- and off-
target scores (Doench, Fusi et al. 2016, Sanson, Hanna et al. 2018). Forward and reverse 
oligos for the sgRNA were synthesized, annealed and ligated into pLenti plasmid 
(Sanjana, Shalem et al. 2014, Shalem, Sanjana et al. 2014). Plasmids were transfected 
into Stable 3 competent E. coli (Thermofisher) for amplification (Sanjana, Shalem et al. 
2014). DNA was purified and sequence verified prior to lentiviral production. To produce 
sgRNA containing lentivirus, 7 x 105 293T cells were seeded into 6-well plates and 
transfected the following day with 1 µg sgRNA, 1 µg psPAX2, 60 ng pVSVG, and 4 µg 
of polyethyleneimine (PEI) in 100 µL DBPS. After 48 h, cell culture supernatant 
containing lentivirus was harvested, centrifuged to remove packing cells, and aliquoted 
and stored at -80o C or -150o C. Viral supernatant with 10 µM Cyclosporin A was added 
to Cas9-expressing BMDMs cultured in BMM for 48 h and was selected with puromycin. 
Validation assays were done 8-10 days post-transduction. 
 
Fluorescence staining and microscopy 
BMDMs were cultured in 96-well plates in the confluency of 30,000 cells/well. 
Following 24-h exposure to AcLDL and/or followed by post LDL 48 h chase from 
lipoproteins. Cells were fixed with 2% paraformaldehyde in PBS for 20 min, blocked and 
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permeabilized with blocking/permeabilization buffer for 10 min. Subsequently cells were 
stained with primary antibodies and 5 µM BODIPY in blocking/permeabilization buffer 
for 1 h, followed by staining with a fluorescent secondary antibody (plus nuclear stain 
and actin stain for downstream cell segmentation) for 45 min. Imaging was done using 
ImageXpress Micro XLS widefield high-content analysis system microscope and 
Olympus IX83 P2ZF microscope.   
 
High-content image analysis and statistical methods 
Image data were quantified using Cell Profiler 3.0.0 (Carpenter, Jones et al. 2006). 
During imaging nine sites per well were image and images with 15-65 cells was 
processed. Nuclei were identified as primary objects and cell boundaries (secondary 
objects) were defined by phalloidin images. From the defined secondary object sum of 
pixel intensities of BODIPY- and perilipin-stained objects were identified as integrated 
intensity. Further data transformations were done using R 3.4.4 (R Development Core 
Team 2018), and, the dplyr (Wickam, Francois et al. 2019), the tidyr (Wickam and Henry 
2019) packages were used. Here, mean and standard deviation was calculated and object 
intensities that were three standard deviations from the mean of each image set were 
flagged  as outliers and discarded. Two-way ANOVA followed by Dunnett multiple 
comparisons were  performed using GraphPad Prism version 8.2.0 for MacOS, GraphPad 
Software (San Diego, California USA) from mean integrated intensities. 
Flow cytometry assay for detecting neutral lipid 
BMDMs were plated on 96 well plates at 10,000 cells/well. Following 24-h exposure to 
AcLDL and/or post-LDL 48-h chase were stained with 5 µM BODIPY (493/503), a 
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neutral lipid dye staining LDs, diluted in DMEM for 5 mins, washed once with cold 
DPBS (-Ca/-Mg) and detached with DPBS (-Ca/-Mg). BMDMs were analyzed for 
BODIPY (493/503) intensity using BD Accuri C6 glow cytometer  
 
Results 
CRISPR-Cas9 whole genome screens identified and ranked genes regulating the neutral 
lipid content of BMDMs 
  We conducted CRISPR-Cas9 whole genome screens (Figure 1) to identify critical genes 
for: 
1. LDL uptake, cholesterol trafficking, and lipid droplet biogenesis by 
identifying sgRNA inserts associated with low- or high-neutral lipid content 
following 24-h AcLDL or OxLDL exposure. This is referred to hereafter by “24-h 
LDL screens”. 
2. Lipid droplet degradation and cholesterol efflux by identifying sgRNA inserts 
associated with low- or high-neutral lipid content following 24-h AcLDL or 
OxLDL exposure, LDL removal and a 36-48 h chase.  This is referred to hereafter 
by “post LDL 48-h chase screens.” 
 We used next generation sequencing to sequence the sgRNA inserts and quality of 
sequencing reads were assessed by FastQC (Supplement Figure 1). Read counts were 
then tabulated and mapped to the Brie library (Supplement Figure 2A-3A). Also, sgRNA 
that were lost from the Brie library were low as shown by input missed sgRNA 
(Supplement Figure 2C-3C). The read counts were normalized (Supplement Figure 2B-
3B). and the read count distributions were analyzed as indicated by the Gini index and the 
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correlation matrix of reads as shown (Supplement Figure 2D-F, Supplement Figure 3D-
F).  
 
Genes leading to low neutral lipid content in BMDMs were validated by targeted sgRNA 
gene disruption  
We identified and ranked critical genes from the 24-h LDL screens. Comparison of 
sgRNA reads among the high- and low-neutral lipid groups from the 24-h LDL screens 
indicated the enrichment of particular genes within one of the groups (Figure 2A). This 
difference in enrichment of all read counts between high- and low-fluorescence groups 
was then statistically analyzed using MAGeCK-RRA to produce a ranked list of genes 
between the low- and high-neutral lipid groups (Supp. Table 1). Here, enrichment 
between groups were demarcated by log base 2 fold change (LFC) indicative of 
enrichment within high (positive LFC) or low (negative LFC) neutral lipid.  
 Comparison of genes enriched in AcLDL and OxLDL in the low neutral lipid 
populations from 24-h whole genome screens we observed that there were genes enriched 
only in AcLDL or only in OxLDL (Figure 2B). Stab-1, a scavenger receptor, was highly 
enriched in both AcLDL and OxLDL. However, Msr1 (SR-A) another scavenger 
receptor, was only highly enriched in the AcLDL screens. Similarly, NPC1, and adaptor 
proteins important clathrin-mediated endocytosis such as Ap2s1, Ap2m1 were only 
highly enriched in AcLDL screens. Also, it should be noted that the vacuolar ATPase, V-
type pump, associated with lysosomes vital for increase pH in the compartments is highly 
enriched in both AcLDL and OxLDL suggesting that the lysosomal degradation of 
modified lipoproteins is regulated by similar machinery. Interestingly,  Soat1, 
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acetyltransferase found in the endoplasmic reticulum , that mediates cholesterol 
conversion to cholesteryl esters was only enriched in the AcLDL low neutral lipid 
populations. These results suggest for the existence of multiple pathways for the uptake 
of modified LDL species depending on the modification. 
 Next, we selected several genes with high LFC and high ranking MAGeCK 
scores, including Atp6v1a, Emc3, and Soat1, that we hypothesized lead to low neutral 
lipid content following gene disruption by lentiviral transduction. As shown by low 
BODIPY and perilipin staining intensity (Figure 2C), 24-h LDL exposure leads to 
significantly lower neutral lipid in the gene disrupted BMDMs compared to wildtype 
BMDM or control BMDM transduced with a non-targeted sgRNA (ScramsgRNA)(data for 
Scram not shown) and Emc3 and Soat1 had significantly fewer lipid droplets as indicated 
by perilipin immunostaining and fluorescent intensity (Figure 2D).  
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Figure 2. 24-h-LDL CRISPR-Cas9 whole genome screens identifies genes leading to low neutral 
lipids, and targeted sgRNA gene disruptions validate screen findings of genes associated with low 
neutral lipid phenotype in BMDMs. Read counts of all sgRNAs from Next-generation sequencing 
were processed and considered. Best performing sgRNAs were assigned a MAGeCK-RRA score based 
on enrichment. Ranked lists were generated based on enrichment comparison between high and low 
neutral lipid groups. A) Read counts from a single 24-h-LDL screen of the four sgRNAs targeting Soat1, 
shows that they had higher read count in low neutral lipid group compared to high neutral lipid group. B) 
Plot of log fold change(LFC) meeting FDR>0.1 between AcLDL and OxLDL for 24-h-LDL screens 
illustrated genes uniquely enriched in either AcLDL or OxLDL and those enriched in both. Here, 
Negative LFC is indicative of low neutral lipid and positive LFC is indicative of high neutral lipid. C) 
Targeted sgRNA disruption of Atp6v1a, vital for increasing luminal pH in late endo-lysosomes, leads to 
decreased LDL uptake resulting in less neutral lipids. Soat1 (ACAT-1), critical for converting free 
cholesterol to  cholesterol esters, disruption leads to lower neutral lipid, however, it is not a complete 
disruption and it could be hypothesized that there are other enzymes compensating cholesterol 
conversion. Emc3, a transmembrane insertase in the endoplasmic reticulum, could potentially be vital for 
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lipid droplet biogenesis as its disruption leads to low neutral lipid. D) Quantification of BODIPY 
493/503 and perilipin integrated intensity of the targeted gene disruptions upon exposure to 24-h 
AcLDL. (Error bars are representative of the standard deviation of the means of all images for a 
genotype, N- is from independent experiments where >100 cells for each genotype were analyzed,*p-
value from Dunnette's test following Two-way ANOVA analysis of genotypes as compared to WT) 
 
 
 
Genes leading to accumulation of neutral lipid in BMDMs post-LDL chase were 
identified and validated by targeted sgRNA gene disruption  
We identified critical genes for the processes of neutral lipid clearance via lipid droplet 
degradation and cholesterol efflux from the post-LDL 48-h chase screens. Here, we 
compared the sgRNA reads from the high- and low-neutral lipid groups from the post-
LDL 48-h chase screens (Figure 3A). MAGeCK-RRA was used to produce a ranked list 
of genes between low- and high-neutral lipid groups (Supplementary Table 1). Next, we 
compared LFC between AcLDL and OxLDL and high overlap of highly ranked and high-
LFC hits was seen suggesting that once lipid droplets are formed the degradation 
machinery involved is independent of the modified LDL species leading to their 
formation (Figure 3B). However, there were genes uniquely enriched in either AcLDL or 
OxLDL that led to accumulation of neutral lipid. Abhd5 and Aurkb only enriched in 
AcLDL and Pol1rb and Dut were only enriched in OxLDL.  Similarly, the comparison of 
AcLDL and OxLDL illustrated that degradation of increased neutral lipids and lipid 
droplets are mediated mostly by autophagy. And, it was seen that autophagy associated 
genes such as Atg9a, Atg101, and Atg13 were highly enriched in both AcLDL and 
OxLDL high neutral lipid populations following post-LDL 48-h chase. 
The nutrient-sensing and cholesterol-sensing pathway were highly enriched in the 
highly fluorescent population post-LDL 48h chase screens suggesting that their loss of 
function leads to an accumulation of neutral lipids. We hypothesized that disruptions to 
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these will lead to high neutral lipid accumulation  as they are unable to detect lipid 
droplets and/or efficiently process neutral lipids for efflux via lysosomal nutrient-sensing 
machinery. We conducted targeted gene disruptions of several vital regulators of nutrient-
sensing machinery such as Tsc1, RagC, Flcn, and Atp6v1a. As shown by post-LDL 48-h 
chase the gene disruptions lead to higher neutral lipid and a higher number of lipid 
droplets as shown by perilipin immunostaining (Figure 3C). However, we were unable to 
quantify the immunofluorescence images using our automated Cell Profiler pipelines as 
our analysis relied on phalloidin staining of images to segment cells and these gene-
disruptions also disrupted the cellular F-actin distribution compared to wild-type cells. 
We conducted flow-cytometry analysis of BODIPY intensity (Figure 3D) and as shown 
the gene disruption led to higher BODIPY fluorescence.  
We also conducted targeted gene disruptions of several genes with high LFC and 
high ranking that included Cbfb, Keap1, Vps11, Bcl6, Szt2, Tgfbr1, and Atg9a. We 
hypothesized that when these genes are disrupted, it will lead to high neutral lipid. As 
shown, the gene disruptions had significantly higher BODIPY intensity post-LDL 48-h 
chase compared to the wild-type and a significantly higher number of lipid droplets as 
shown by perilipin immunostaining (Figure 4B) 
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Figure 3. Post-LDL 48h chase CRISPR-Cas9 whole genome identified gene disruptions leading to 
accumulation of neutral lipid and targeted sgRNA gene disruptions validate screen findings by 
recapitulating the high-neutral lipid phenotype. Read counts of all sgRNAs from Next-generation 
sequencing were processed and considered. Ranked lists were generated based on enrichment comparison 
between high and low neutral lipid groups. A) Read counts from a single post-LDL-48-h chase screen of the 
four sgRNAs targeting Flcn, shows that they had higher read count in high neutral lipid group compared to 
low neutral lipid group. B) Plot of log fold change (LFC) meeting FDR > 0.1 between AcLDL and OxLDL for 
post-LDL chase screens illustrated genes uniquely enriched in either AcLDL or OxLDL and those enriched in 
both.. Here, Negative LFC is indicative of low neutral lipid and positive LFC is indicative of high neutral 
lipid. C) BODIPY 493/503 was used to stain neutral lipid and perilipin, lipid droplet associated protein, was 
used to identify lipid droplets After chase sgRNA disrupted BMDMs led to high neutral lipid as shown by 
high BODIPY intensity compared to WT. Regulators of the nutrient sensing pathway are vital for cholesterol 
sensing too as cell with disrupted Tsc1 by targeted sgRNA has high neutral lipids as lipid droplets post-48-h 
chase compared to WT. Similarly, RagC disrupted cells too have high neutral lipid as lipid droplets. However, 
Flcn disruption led to   high neutral lipid (high BODIPY) but not high lipid droplets. In the same way, 
Atp6v1a disruption too leads to accumulation of neutral lipid. However, as shown previously Atp6v1a had low 
neutral lipid post 24h LDL exposure however overtime in culture leads to accumulation of neutral lipids too  
D) As shown by flow cytometry, sgRNA disruption led to high neutral lipid content after chase as confirmed 
by high geometric means of BODIPY intensity (N=2 is from independent experiments where at least 1x104 
cells were analyzed) 
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Figure 4. Targeted sgRNA-gene disruption validates screen findings of neutral lipid accumulation 
phenotype in BMDMs,  Genes identified leading to accumulation of neutral lipids post-LDL-48-h chase 
from CRISPR-Cas9 whole-genome screens were validated by targeted sgRNA gene disruption. A) As 
shown sgRNA gene disruption led to high neutral lipid content post-LDL-48H chase. B) Quantification 
of BODIPY and perilipin integrated intensity (Error bars are representative of the standard deviation of 
the means of all images for a genotype, N- is from independent experiments where >100 cells for each 
genotype analyzed,*p-value from Dunnette's test following Two-way ANOVA analysis of genotypes as 
compared to WT) 
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Ranked lists were used to identify gene sets of enriched biological pathways  
 In order to identify the biological pathways and gene-sets enriched within our 
ranked lists of genes, we performed gene set enrichment analysis (GSEA) using 
Reactome database (Figure 5A; full sets Supplementary Table 2 and Table 3). Within the 
24-h AcLDL screen ranked gene list, a high number of genes from vesicle-mediated 
trafficking and signaling pathways such as signaling by insulin receptor, iron uptake and 
transport, and cilium assembly were highly enriched (Figure 5B). In the same way, Golgi 
transport associated pathways such as ER to Golgi anterograde transport, COPI-mediated 
anterograde transport, transport to Golgi and subsequent modification, and intra-Golgi 
traffic were highly enriched. The enrichment of Golgi-associated gene-sets points 
towards a strong association of the Golgi-apparatus with LDL trafficking, processing and 
lipid droplet biogenesis. We then examined the performance of the identified gene sets in 
our CRISPR-Cas9 whole-genome screens. Briefly, we extracted the genes from these 
pathways that had FDR < 0.1 and their respective LFC from all screens (Figure 5C). 
Here, the negative log changes are associated with lower neutral lipid content and 
positive log fold change is associated with higher neutral lipid content for the given 
sgRNA. Screen performance of gene-sets identified in pathway enrichment analysis show 
low neutral lipid content consistent with the above-mentioned pathways and suggesting 
critical cellular processes underlying LDL uptake, cholesterol processing and lipid 
droplet biogenesis. Pathways such as signaling by insulin receptor and iron uptake 
transport are highly enriched as they contain components of the vacuolar ATPase 
complex (Figure 5C). Vacuolar ATPase H+ pump subunits, which are crucial in ATP 
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hydrolysis coupled transmembrane transport, the disruption of the luminal V0 subunit 
members Atp6v0b, Atp6v0c, Atp6v0d1 lead to lower neutral lipid content. Furthermore, 
the disruption of the cytoplasmic V1 subunit members Atp6v1a, Atp6v1b2, Atp6v1d, 
Atp6v1e1, Atp6v1b2 had ambiguous neutral lipid content. The Golgi apparatus associated 
conserved oligomeric complex proteins Cog2, Cog3, Cog4, Cog6, Cog7, Cog8, and 
endoplasmic reticulum membrane complex proteins Emc1, Emc2, Emc3, Emc4, Emc6 
and Emc7 led to low neutral lipid content in all screens. Similarly, we examined the 
performance of canonical pathways and machinery previously described in the literature 
as being vital for LDL processing and lipid droplet biogenesis (Figure 5D). 
  A similar GSEA analysis was carried out with the post-LDL 48-h chase screens 
ranked list. From the enriched Reactome pathways (Figure 6A) gene sets from regulation 
of PTEN gene transcription, regulates metabolic genes, macroautophagy, and activation 
of ATR in response to stress screen were highly enriched (Figure 6B). Similar to above, 
the screen performance of genes in these gene sets was analyzed (Figure 6C), and sgRNA 
read counts corresponding to these genes was enriched in cells sorted into the high 
neutral lipid pools suggesting that CRISPR/Cas9 disruption of these genes impairs 
efficient degradation of lipid droplets and/or efflux of cholesterol. The autophagy-related 
genes Atg9a, Atg13, Atg14, and Atg101 were all enriched in the post-LDL-48-h screens 
suggesting that autophagy machinery promotes degradation of lipid droplets and clearing 
of neutral lipids from macrophages. 
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Figure 5. Ranked gene lists leading to low neutral lipid content can be mapped to enrichment in 
biological pathways and gene-sets. A) Pathway tree from Gene Set Enrichment Analysis (GSEA), 
shows the highly enriched biological pathways and gene-sets within the ranked list of genes from 24-h 
AcLDL screens within the Reactome database. B) Selected trafficking pathways were highly enriched 
with high number of genes within the ranked list C) sgRNA disruption of genes of these enriched 
pathways leads to low neutral lipids. However, some have ambiguous performance in screens. D) 
Disruption of canonical genes associated with processes of LDL uptake and processing, lipid droplet 
degradation led to neutral lipid distribution as expected. Negative log-fold change is associated with 
low-neutral lipid content and positive log-fold change is associated with high-neutral lipid content. 
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Figure 6. Ranked gene lists leading to accumulation of neutral lipid can be mapped to identify 
enriched biological pathways and gene-sets A) Pathway tree from Gene Set Enrichment Analysis 
(GSEA), shows the highly enriched biological pathways within the ranked list of genes from post-LDL 
48-h chase screens using the Reactome database. B) Selected pathways were enriched with high number 
of genes within the ranked list.  C) sgRNA disruption of genes of these enriched pathways leads to high 
neutral lipids. Negative log-fold change is associated with low-neutral lipid content and positive log-fold 
change is associated with high-neutral lipid content. 
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Discussion 
 
 In the present study, we identified and ranked genes contributing to cholesterol 
metabolism in BMDMs by interrogating the neutral lipid content in gene-disrupted 
mutants screened at two conditions. To do this, we implemented  a series of CRISPR-
Cas9 whole-genome screens followed by comprehensive bioinformatics analysis, 
targeted gene disruptions and phenotype validations, and gene set enrichment analysis. 
From our 24-h LDL screens, we identified and ranked critical genes whose disruption led 
to low cellular neutral lipid phenotypes (Figure 2). These genes may be regulating 
cellular processes such as vesicle-mediated LDL trafficking, lysosomal cholesterol 
processing or lipid droplet biogenesis. Similarly, in our post-LDL-48-h chase screens we 
identified and ranked genes leading to accumulation of neutral lipids following LDL 
removal. We validated post-LDL-48h chase screens result by using targeted gene 
disruptions (Figure 3-4) of a subset of these gene hits with results leading to low or an 
accumulation of neutral lipid. Our targeted sgRNA gene disruption shows that the ranked 
lists of genes identified from our screens are critical regulators for cholesterol 
metabolism. We also compared if there are differences in neutral lipid dynamics in 
response to AcLDL or OxLDL exposure with our screens, and we observed that there are 
some genes that only enriched either AcLDL or OxLDL as well as some that were 
common to both (Figure 2B, Figure 3B). Specifically, in 24h-LDL screens Msr1 was only 
enriched in AcLDL low neutral lipid population and not in OxLDL however, Stab1, 
another scavenger receptor was enriched in the low neutral lipid population of both 
suggesting that some receptors and machinery maybe sensitive to the LDL modification. 
Similarly, genes of lysosomal nutrient sensing machinery were enriched in high 
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fluorescence high neutral lipid populations in all AcLDL and OxLDL screens in 24-h 
LDL and post-LDL 48h chase screens suggesting that this machinery is crucial for events 
of clearing neutral lipid within BMDMs regardless of the LDL source. And, in post-LDL 
48h chase screens autophagy machinery associated genes were enriched in the neutral 
lipid accumulated populations in both AcLDL and OxLDL highlighting autophagy 
mediated degradation of accumulated lipid droplets and neutral lipids. However, it should 
be noted that we did not perform replicate screens using OxLDL in this work. 
Importantly, we identified novel genes and organelle specific protein complexes.  
 By GSEA analysis of ranked gene lists we were able to identify highly enriched 
biological pathways and  gene-sets. GSEA revealed the gene-sets highly enriched in 24-
h-LDL screens are associated with Golgi trafficking, Golgi to endoplasmic reticulum 
trafficking and ATP-hydrolysis coupled transport (Figure 5). In the same way, within our 
post-LDL-48-h chase ranked lists gene sets of the macroautophagy, regulation of PTEN 
gene transcription, regulates metabolic genes, and activation of ATR in response to stress 
were highly enriched (Figure 6). 
 LDL uptake is mediated mainly by receptor-mediated endocytosis and other 
cellular uptake mechanisms such as macropinocyotosis too contribute to LDL intake to 
cells. On exposure to LDL there is an increased localization of cholesterol to the plasma 
membrane, endoplasmic reticulum and, golgi apparatus and the exact regulators or the 
mechanisms responsible are yet to be uncovered (Maxfield and Tabas 2005). Endocytic 
vesicles fuse with lysosomes hydrolyzing the  LDL to derive free cholesterol. According 
to our current understanding this process is directed by lysosomal resident NPC-1 and 
NPC-2 which then facilitate transport to cellular locations such as the endoplasmic 
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reticulum and Golgi apparatus. At the endoplasmic reticulum cholesterol is esterified to 
form neutral lipids and are stored as lipid droplets by the action of ACAT1 (Soat1). 
Interestingly, in our screens ACAT1 was only enriched in AcLDL and not in OxLDL 
which could be due to compensatory action of other proteins facilitating the formation of 
neutral lipids (Tabas 2002, Neculai, Schwake et al. 2013, Pfisterer, Peränen et al. 2016).  
 The Golgi apparatus may play a central role in the coordination of events 
following LDL uptake. The high enrichment of Golgi trafficking and endoplasmic 
reticulum associated gene-sets (Figure 5B) in low neutral lipid population in 24-h LDL 
screens suggests the critical association between the Golgi apparatus and the endoplasmic 
reticulum for the processes of LDL trafficking, processing and lipid droplet biogenesis in 
BMDMs. Specifically, our gene-set analysis  reveal that genes that are part of the Golgi 
apparatus conserved oligomeric complex (COG) are highly enriched (Figure 5C). Here, 
COG lobe A proteins Cog1, Cog2, Cog4 and lobe B proteins Cog7 and Cog 8 were hits. 
Previous work has shown that the conserved COG complex interacts with tethering and 
fusion complexes in endocytic and secretory pathways (Oka, Vasile et al. 2005, Smith 
and Lupashin 2008) and the trans-Golgi system is vital in sorting and recycling scavenger 
receptors during LDL endocytosis and cholesterol trafficking (Mori, Takahashi et al. 
1994). Our screen findings suggest a possible role for COG-complex proteins in directing 
of cholesterol trafficking and signaling events following LDL uptake. Therefore, we 
hypothesize that the Golgi apparatus could have a role in directing LDL-derived 
cholesterol to organelles such as the endoplasmic reticulum.  
 Similarly, our gene-set analysis revealed that the endoplasmic reticulum 
membrane complex (EMC) proteins are highly enriched in the low neutral lipid 
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population in 24-h LDL screens (Figure 5D). Disruptions to proteins that are part of the 
EMC which are transmembrane domain insertase proteins; Emc1, Emc2, Emc3, Emc4, 
Emc6 and Emc7 led to low neutral lipid content in LDL rich conditions. We show that 
Emc3sgRNA cells can take up LDL and form neutral lipids but significantly less than the 
wild-type. This inefficiency could be due to increased neutral lipid accumulation at the 
endoplasmic reticulum leaflets and disrupted lipid droplet biogenesis due disruption to 
the EMC. Thus, suggesting an important role for EMC in coordinating the processing of 
neutral lipids and consequently in the formation of lipid droplets in BMDMs. Previously 
it has been shown that EMC upregulates Soat1 (ACAT1), cholesterol esterification 
enzyme , facilitating lipid droplet biogenesis (Pol, Gross et al. 2014, Volkmar, Thezenas 
et al. 2019). We show that disruption of Soat1 leads to low neutral lipids. However, in 
targeted knockout experiments, Soat1sgRNA cells were not completely depleted of neutral 
lipid compared to wild-type but had significantly less suggesting action of multiple 
acyltransferases in esterification of cholesterol in the endoplasmic reticulum.  
 Vacuolar-ATPase (V-ATPase) pump machinery components were highly 
enriched in the low neutral lipid population of the 24-h LDL screens. These machinery 
components are vital for  acidifying endocytic vesicles and promote membrane fusion in 
endosomal-lysosomal fusion (Kissing, Hermsen et al. 2015). We hypothesized that loss 
of function in these components prevents efficient degradation of LDL thus leading to 
overall lower uptake of LDL. Specifically, the disruption to the V0, the luminal subunit 
components were overall enriched in low neutral lipid populations. However, the V1 
subunit, which are the cytoplasmic subunit components were enriched in the high neutral 
lipid population of post-LDL-48h chase screens. Previous studies have shown that the V-
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ATPase is also vital for nutrient sensing as well as cholesterol sensing  (Castellano, 
Thelen et al. 2017) we hypothesize that V-.ATPase is vital for sensing lipid droplets and 
signaling for their subsequent degradation. 
 In reverse cholesterol transport, lipid droplets can be degraded by autophagy 
(Dong and Czaja 2011) and/or lipolysis (Ducharme and Bickel 2008) to derive 
cholesterol which can be used for cellular needs of be effluxed to high-density 
lipoproteins mediated by plasma membrane bound ATP-dependent binding cassette 
proteins (Oram 2003). We show that targeted disruption of the autophagy-related gene, 
Atg9a  leads to accumulation of neutral lipid after chase (Figure 4). Similarly, we show 
that disruption of Tgfbr  (TGF-b receptor) leads to high neutral lipid accumulation after 
chase (Figure 4) suggesting that TGF-b signaling somehow regulating lipid droplet 
degradation or cholesterol efflux. Previous studies have shown that TGF-b signaling 
leads to increased autophagy by upregulation of Atg5, Atg7, and Becn1 (Kiyono, Suzuki 
et al. 2009).  
 Our results show that disruption of Keap1 (Kelch Like ECH Associated Protein1) 
or Cul3 (Culin3), scaffold protein, which are part of the Keap1-Cul3 E3 ubiquitin ligase 
that polyubiquitinates Nrf2 for proteasomal degradation (Canning and Alex 2014) leads 
to higher neutral lipids accumulation. Additionally, disruption of Nrf2 led to low neutral 
lipid content. Nrf2, which is a transcription factor, plays a crucial role in macrophage 
response to OxLDL and to oxidative stress (Sussan, Jun et al. 2008, Mimura and Itoh 
2015), suggesting a potential role for oxidative response in mediating lipid droplet 
degradation. 
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 We show that disruption of nutrient sensing machinery components and their 
regulators such as RagA, RagC, Flcn, Tsc1, Tsc2, Atp6v1a, Lamtor1, Lamtor2, Lamtor3, 
and Lamtor4 leads to high neutral lipid content. Previous work has shown that nutrient 
sensing machinery is also vital for cholesterol sensing (Castellano, Thelen et al. 2017), 
but it is unclear how lysosomal sensing of cholesterol content impacts lipid droplet 
biology.  
 In conclusion, in this study we present ranked lists of critical genes leading to 
high or low neutral lipid content in macrophages. Using targeted sgRNA knockouts we 
further confirm and validate the findings from our CRISPR-Cas9 whole-genome screens 
by recapitulating the screen low- and high-neutral lipid phenotypes. This work 
contributes to improved understanding of the biological process involved in neutral lipid 
metabolism as well as aids in identifying potential drug targets against cardiovascular 
disease. Further, we confirm previously described genes associated with processes of 
LDL uptake and trafficking, including genes associated with cholesterol processing and 
autophagy. Similarly, we present novel proteins such as Emc3 and Atg9a as critical for 
efficient neutral lipid metabolism in BMDMs.  
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Chapter III 
Conclusions 
 
Golgi apparatus conserved oligomeric complex and endoplasmic reticulum 
membrane protein complex are critical for LDL processing as revealed by CRISPR-
Cas9 whole genome screens  
 
  Low-density lipoprotein (LDL) endocytosis elevates cellular cholesterol  
increasing localization to the plasma membrane and cholesterol esterification by  
endoplasmic reticulum to be sequestered as lipid droplets (Moore and Tabas 2011). The 
critical genes involved in trafficking LDL-cholesterol from lysosomes to other cellular 
destinations such as Golgi-apparatus and endoplasmic reticulum are unclear. Currently, 
there is evidence supporting a path for cholesterol from lysosomal compartments directly 
to the plasma membrane and after saturation cholesterol is redirected to the endoplasmic 
reticulum for sequestration as lipid droplets (Neculai, Schwake et al. 2013, Das, Brown et 
al. 2014). Similarly, there is evidence for cholesterol saturation in the Golgi apparatus 
and trafficking to plasma membrane or endoplasmic reticulum (Blanchoin, Boujemaa-
Paterski et al. 2014).  
  The Golgi apparatus is vital for possible scavenger receptor recycling and 
vesicle-mediated cholesterol trafficking to endoplasmic reticulum (Mori, Takahashi et al. 
1994, Urano, Watanabe et al. 2008). In our 24-h LDL populations the Golgi apparatus 
conserved oligomeric complex (COG)  lobe A proteins Cog1, Cog2, Cog3, Cog4, and 
lobe B proteins Cog7, Cog8, as well as Nrbp1, Exoc1, Mon2, and Uvrag had low neutral 
lipid content. Suggesting that the Golgi apparatus may have a central role in cholesterol 
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processing in BMDMs and disruption of any of the above genes leads to inefficient 
cholesterol metabolism. Further, hypertrophy of the Golgi apparatus upon exposure to 
OxLDL has been shown in pigeon macrophages and THP-1 cells (Jerome, Cash et al. 
1998). 
 Similarly, cholesterol resulting from LDL exposure is esterified  in the 
endoplasmic reticulum to prevent toxicity. Here, the endoplasmic reticulum membrane 
protein complex (EMC) upregulates ACAT-1 (Soat1) acyltransferase  (Pol, Gross et al. 
2014, Volkmar, Thezenas et al. 2019). In our 24-h-LDL populations EMC components 
Emc1, Emc2, Emc3, Emc4, Emc6, and Emc7 led to low neutral lipid. And, we show with 
targeted sgRNA knockout of Emc3 leads to less neutral lipid content and less lipid 
droplets. Thus, this work supports the current understanding that lipid droplet formation 
in BMDMs in the endoplasmic reticulum is coordinated by EMC complex regulation of 
cholesteryl ester formation via Soat1. In (Volkmar, Thezenas et al. 2019) work with 
Emc6 mutants, it was seen that siRNA and sgRNA knockouts lead to a significant 
decrease in cholesteryl ester levels compared to wild-type. Also, in alveolar type-II cells, 
it has been shown that Emc3 mutants have downregulated Soat1 (Tang, Snowball et al.).  
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Figure 1. Model for critical role of conserved-oligomeric complex of Golgi and endoplasmic 
reticulum membrane complex in LDL derived cholesterol regulation, A) Proposed trafficking route 
of LDL to be subsequently packaged as a lipid droplet , B) disruptions to conserved-oligomeric complex 
proteins and the endoplasmic reticulum membrane complex as indicated led to low neutral lipid content 
in 24-h-LDL screens 
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Model for low-density lipoprotein uptake, lipid droplet formation and degradation, 
and cholesterol metabolism in BMDMs 
 Whole genome CRISPR-Cas9 screens were able to identify critical genes 
associated with LDL uptake and trafficking, lipid droplet formation and degradation, and 
cholesterol metabolism. We show that targeted sgRNA disruption of identified hits lead 
to lower or higher neutral lipid content in BMDMs. Scavenger receptor-bound LDL are 
endocytosed in clathrin-coated vesicles. These vesicles are degraded by fusion with 
lysosomes to derive cholesterol.  Cholesterol is then trafficked to the plasma membrane 
or  to the endoplasmic reticulum for esterification to be sequestered as lipid droplets. This 
process can be reversed to derive cholesterol by  degradation of lipid droplets.  We show 
that there is a requirement for the coordinated activity of multiple pathways and their 
associated regulators for efficient cholesterol metabolism in BMDMs.   
 
 
Figure 2. CRISPR-Cas9 whole-genome screens identify critical genes for neutral lipid metabolism in 
BMDMs exposed to modified LDL. sgRNA disruption of the genes shown led to low or high neutral lipid 
content in BMDMs indicating their critical role in LDL-endocytosis, vesicular cholesterol trafficking, 
cholesterol processing to generated lipid droplets, or degradation of lipid droplets.   
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Rab7
VPS11
Acap2, Arf6
Rabggta,Rabggtb
RagA
RagC
Flcn
Hdac3
Atp6v1a
Lamtor1-4 Atg9a 
Atg13
Atg14
Abca1
Low fluorescence neutral lipid in sgRNA gene-disruption
High fluorescence neutral lipid in sgRNA gene-disruption
Post Golgi vesicle 
trafficking
Cholesteryl ester 
conversion
LD Degradation
Cholesterol 
Efflux
Cul3 
Keap1
Nrf2
Arcn1
Nrbp1
Ykt6
Atp6v1a
Atp6v1b2
Atp6v1e1
Atp6v1f
Atp6v1h
Lipid 
droplets
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 In conclusion, this work provides a comprehensive ranked list of critical genes for 
understanding the vital genes and biological pathways associated with the processes of 
LDL uptake, cholesterol trafficking, lipid droplet formation and degradation, and 
cholesterol efflux. This work can aid scientist in generating hypothesis for comprehensive 
studies focused on mechanistic understanding of the undelying biology as well as in 
identifying new therapeutic targets for treating diseases such as atherosclerosis and other 
cardio vascular diseases.  
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Supplement 
 
  
 
Supplement-Figure-1 
FastQC quality control of NGS reads, A) 75 base pair long region containing adaptor sequences and 
sgRNA insert was sequenced in all samples (A-I) (statistics of one such fastq file is shown) with highly 
accurate >99.9% base calling (A-II) (indicated by high Phred score)  B) Sequences were trimmed to get 
20 base pair sgRNA inserts using Cutadapt (B-I) and the sgRNA insert base calling was highly accurate 
as indicated by high Phred score (B-II). All fastq files from next generation sequencing was assessed 
using FastQC prior to and after trimming using Cutadapt and was consistently of high base calling 
quality. 
 
A
B
I II
I II
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Supplement-Figure-2 
MAGeCK-VISPR quality control of NGS reads, A) High percentage of sequencing reads from NGS 
FASTQ files were mapped to the Brie library in all screens. B) MAGeCK normalizes read counts before 
RRA analysis and read counts were uniform across screens, C) Missed gRNAs are indicative of sgRNAs 
found in the library but not the samples  D) Gini index score is indicative of evenness of  reads in the 
group,  E) Cumulative distribution for sample reads, F) Correlation matrix for sample   
 
 
24H AcLDL Screen 1
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Supplement-Figure-3 
MAGeCK-VISPR quality control of NGS reads, A) High percentage of sequencing reads from NGS 
FASTQ files were mapped to the Brie library in all screens. B) MAGeCK normalizes read counts before 
RRA analysis and read counts were uniform across screens, C) Missed gRNAs are indicative of sgRNAs 
found in the library but not the samples  D) Gini index score is indicative of evenness of  reads in the 
group, E) Cumulative distribution for sample reads, F) Correlation matrix for sample   
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